EUVIMEDEUVIMED entdecken
Crossref

Routine detection of reactive Cyfra21-1-specific CD8+ T cells and its predictive value for responsiveness to PD-1/PD-L1 inhibitor therapy in NSCLC patients

Shilong Song, Yandan Wu, Yu Zhao, Guangyu Zhao, Min Li, Yi Wu, Suyue Zhu, Fangping Yue, Chunyan Chen, Hao Jiang, Chuanlai Shen

Translational Research · 2026

DOI: 10.1016/j.trsl.2026.02.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2026. Verfasst von Shilong Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antigens, Neoplasm, Lung Neoplasms, CD8-Positive T-Lymphocytes. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors are widely used in non-small cell lung cancer (NSCLC), but with limited overall response rates. Indicators predicting immunotherapy response are hard to routinely detect due to their invasiveness. This study systematically screened for CD8+T-cell epitopes in Cytokeratin Fragment Antigen 21-1 (Cyfra21-1), a valuable NSCLC tumor marker, through a combination of in silico prediction, ex vivo co-cultures of peptides with patient-derived peripheral blood mononuclear cells (PBMCs), peptide competition binding assays, and peptide immunization in humanized mice. A total of 37 novel CD8+T-cell epitopes were confirmed to exhibit immunogenicity in a real-world lung cancer cohort comprising 150 patients. These epitopes were restricted by 13 HLA-A, 15 HLA-B, and 14 HLA-C prevalent allotypes which cover the majority of Northeast Asian population. Using these epitope peptides, a universal ELISpot assay was established to count reactive Cyfra21-1-specific CD8+T cells, and a cohort of 70 NSCLC patients scheduled to receive PD-1/PD-L1 inhibitor therapy was tested. The baseline count of reactive Cyfra21-1-specific CD8+T cells in PBMCs was identified as an independent predictor of patient responsiveness to immunotherapy, with an AUC of 0.757 and a cut-off value of 25.5 SFUs/4 × 10⁵ PBMCs that distinguished responders from non-responders. This study is the first to construct a broad-spectrum CD8+T-cell epitope library of the Cyfra21-1 antigen in Northeast Asians, establish a universal assay for measuring Cyfra21-1-specific CD8+T cell reactivity, and validate the predictive value of Cyfra21-1-specific CD8+T cells for immunotherapy response in NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAntigens, NeoplasmLung NeoplasmsCD8-Positive T-LymphocytesKeratin-19Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsB7-H1 AntigenHumansFemaleMaleAnimalsMiddle AgedEpitopes, T-LymphocytePredictive Value of TestsAgedMice

Stichwörter der Autor:innen

Cyfra21-1ELISpot assayHLANSCLCPD-1/PD-L1 inhibitor therapyT-cell epitopes

Substanzen

Antigens, Neoplasmantigen CYFRA21.1Keratin-19Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsB7-H1 AntigenEpitopes, T-LymphocytePDCD1 protein, humanCD274 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.
  • State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China; Joint Research Center for Regional Diseases of IHM, Bengbu Medical University, Bengbu, Anhui, China; Jo…
  • Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China. Electronic address: chuanlaishen@seu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Song, S., Wu, Y., Zhao, Y., Zhao, G., Li, M., Wu, Y., Zhu, S., Yue, F., Chen, C., Jiang, H., & Shen, C. (2026). Routine detection of reactive Cyfra21-1-specific CD8+ T cells and its predictive value for responsiveness to PD-1/PD-L1 inhibitor therapy in NSCLC patients. Translational Research. https://doi.org/10.1016/j.trsl.2026.02.010

Vancouver

Song S, Wu Y, Zhao Y, Zhao G, Li M, Wu Y, et al. Routine detection of reactive Cyfra21-1-specific CD8+ T cells and its predictive value for responsiveness to PD-1/PD-L1 inhibitor therapy in NSCLC patients. Translational Research. 2026. doi:10.1016/j.trsl.2026.02.010

BibTeX
@article{Song2026,
  author = {Song, Shilong and Wu, Yandan and Zhao, Yu and Zhao, Guangyu and Li, Min and Wu, Yi and Zhu, Suyue and Yue, Fangping and Chen, Chunyan and Jiang, Hao and Shen, Chuanlai},
  title = {Routine detection of reactive Cyfra21-1-specific CD8+ T cells and its predictive value for responsiveness to PD-1/PD-L1 inhibitor therapy in NSCLC patients},
  journal = {Translational Research},
  year = {2026},
  doi = {10.1016/j.trsl.2026.02.010}
}
Kostenlos starten →